Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimers disease mice
Ultomiris (ravulizumab-cwvz) Indication(s): Multiple rare, complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) Manufacturer(s): Alexion/AstraZeneca 2024 Sales: $3.92 billion Why it sold so well: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is emerging as a hematology drug to watch in 2025, driven by strong commercial momentum and expanding clinical uptake in 2024
But what do you do with that squiggly line from your watch
Treatment duration and tapering are always guided by a medical doctor
US$ 24.90
US$ 24.48
US$ 29.97
US$ 22.46
US$ 26.52
US$ 23.64
